Key result
Rhein cuts hypoxic cardiac fibroblast αSMA by ~85%, driven by HDAC inhibition.
Why the study?
Excessive extracellular matrix production leads to maladaptive cardiac fibrosis and dysfunction, motivating investigation of Rhein's anti-fibrotic potency in human myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for rhein in cardiac fibrosis; in vivo and clinical studies required before any therapeutic consideration.
Although fibrosis depicts a reparative mechanism, maladaptation of the heart due to excessive production of extracellular matrix accelerates cardiac dysfunction. The anthraquinone Rhein was examined for its anti-fibrotic potency to mitigate cardiac fibroblast-to-myofibroblast transition (FMT). Primary human ventricular cardiac fibroblasts were subjected to hypoxia and characterized with proteomics, transcriptomics and cell functional techniques. Knowledge based analyses of the omics data revealed a modulation of fibrosis-associated pathways and cell cycle due to Rhein administration during hypoxia, whereas p53 and p21 were identified as upstream regulators involved in the manifestation of cardiac fibroblast phenotypes. Mechanistically, Rhein acts inhibitory on HDAC classes I/II as enzymatic inhibitor. Rhein-mediated cellular effects were linked to the histone deacetylase (HDAC)-dependent protein stabilization of p53 under normoxic but not hypoxic conditions. Functionally, Rhein inhibited collagen contraction, indicating anti-fibrotic property in cardiac remodeling. This was accompanied by increased abundance of SMAD7, but not SMAD2/3, and consistently SMAD-specific E3 ubiquitin ligase SMURF2. In conclusion, this study identifies Rhein as a novel potent direct HDAC inhibitor that may contribute to the treatment of cardiac fibrosis as anti-fibrotic agent. As readily available drug with approved safety, Rhein constitutes a promising potential therapeutic approach in the supplemental and protective intervention of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Barbosa et al. (2020) studied Cardiac fibrosis (in vitro model) (n=5). Rhein vs. Untreated control (normoxia, hypoxia, or TGFβ1 alone) was evaluated on αSMA protein abundance under hypoxia (85% reduction, p=<0.05). Rhein significantly reduced αSMA protein abundance by 85% under hypoxic conditions and inhibited HDAC activity by 70%, demonstrating potent anti-fibrotic properties in human cardiac fibroblasts.
Synapse has enriched 10 related papers. Consider them for comparative context: